Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume 12, Issue 4, Pages 355-360Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/pcan.2009.21
Keywords
prostatic neoplasms; utilization; health-care costs
Categories
Funding
- GlaxoSmithKline Inc
Ask authors/readers for more resources
Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13 091, prevention strategies have the potential to reduce health-care costs. Prostate Cancer and Prostatic Diseases (2009) 12, 355-360; doi: 10.1038/pcan.2009.21; published online 26 May 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available